Join Us at the 2025 MASH-TAG Conference: Galectin Therapeutics Takes the Stage!
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented during the 2025 MASH-TAG Conference, being held January 9-11, 2025 in Park City, Utah.
Exciting Updates on Galectin Therapeutics
As we gear up for the highly anticipated 2025 MASH-TAG Conference, Galectin Therapeutics is proud to share that the top-line results of the NAVIGATE trial will be revealed during this groundbreaking event. This is a significant milestone for the Company, as they continue to lead the way in developing therapeutics that target galectin proteins.
Patients with MASH cirrhosis and portal hypertension have long awaited advancements in treatment options, and Galectin Therapeutics is at the forefront of research and development in this area. The NAVIGATE trial is expected to provide valuable insights into the efficacy of belapectin in addressing these conditions.
During the conference, attendees will have the opportunity to learn more about the innovative therapies being developed by Galectin Therapeutics and how they could potentially transform the landscape of MASH cirrhosis and portal hypertension treatment.
Engaging with External Stakeholders
In addition to presenting the top-line results of the NAVIGATE trial, Galectin Therapeutics’ executive leadership will be hosting one-on-one meetings in San Francisco from January 13-16, 2025, during the JP Morgan Healthcare Conference.
External stakeholders are invited to engage with the Company’s leadership team, learn more about the NAVIGATE trial results, and participate in discussions regarding the future of the belapectin program. This presents a unique opportunity for collaboration and exploration of potential next steps in advancing the treatment of MASH cirrhosis and portal hypertension.
How Will This Affect Me?
As a patient suffering from MASH cirrhosis or portal hypertension, the presentation of the NAVIGATE trial results at the 2025 MASH-TAG Conference could have a significant impact on your treatment options. The insights gained from this trial could lead to new therapeutic approaches that offer improved outcomes and quality of life for individuals with these conditions.
How Will This Affect the World?
The advancements in treatment for MASH cirrhosis and portal hypertension that may result from the NAVIGATE trial could have far-reaching implications for global healthcare. By addressing unmet medical needs and introducing innovative therapies, Galectin Therapeutics’ research could improve treatment standards and outcomes for patients worldwide.
Conclusion
Join us at the 2025 MASH-TAG Conference as we witness Galectin Therapeutics take the stage to present the top-line results of the NAVIGATE trial. This event marks a significant step forward in the development of therapies for MASH cirrhosis and portal hypertension, with the potential to positively impact patients and the healthcare community at large. Don’t miss this opportunity to be part of a groundbreaking moment in medical research and innovation.
